Routine Health Screening Market Report 2025

This routine health screening market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The routine health screening market size has grown strongly in recent years. It will grow from $54.28 billion in 2024 to $58.45 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing awareness of preventive healthcare, the rising prevalence of chronic diseases, growing government initiatives for early disease detection, the aging global population, and the expansion of healthcare infrastructure.

The routine health screening market size is expected to see strong growth in the next few years. It will grow to $77.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to the growing adoption of personalized medicine, increasing focus on chronic disease management, expansion of healthcare access in emerging markets, rising healthcare spending, and greater public and private investment in preventive health programs. Major trends in the forecast period include the integration of artificial intelligence for improved diagnostic accuracy, expansion of health screening services through telemedicine platforms, heightened focus on preventive care driven by public health initiatives, enhanced patient engagement through mobile health apps and digital health platforms, and the development of advanced biomarker-based screening technologies.

The growing awareness of preventive healthcare is expected to boost the routine health screenings market in the future. Preventive healthcare involves practices and measures aimed at preventing diseases and health conditions through early detection, lifestyle changes, and proactive interventions. Increased awareness of preventive healthcare is due to its advantages in early disease detection, improved health outcomes, and cost savings, driven by enhanced public education and medical advancements. Routine health screenings support preventive healthcare by identifying potential health issues early, enabling timely interventions, and reducing the risk of severe diseases. For example, the National Health Service (NHS) reported in May 2023 that 2,302,400 diagnostic tests were conducted in March 2023, an increase of 223,100 tests compared to March 2022. By the end of March 2023, the number of patients waiting for a key diagnostic test had risen to 1,628,300, an increase of 59,400 from March 2022. This indicates that the rising awareness of preventive healthcare is driving growth in the routine health screenings market.

Leading companies in the routine health screenings market are focusing on developing advanced solutions, such as lung cancer screening tests, to gain a competitive advantage. These tests are designed to detect lung cancer early in individuals at high risk, even before symptoms appear. For instance, in October 2023, DELFI Diagnostics, Inc., a U.S.-based diagnostic technology company, launched the FirstLook Lung test, an innovative blood test aimed at improving lung cancer screening. FirstLook Lung uses fragmentomics to analyze patterns in cell-free DNA (cfDNA) from blood samples and employs advanced machine learning to distinguish between cancerous and non-cancerous patterns. With a 99.7% negative predictive value (NPV), the test accurately identifies potential lung cancer cases while reducing the need for unnecessary low-dose CT (LDCT) scans. FirstLook Lung is integrated into routine blood tests to improve screening rates, especially among underserved populations, and features a scalable whole-genome machine-learning platform that could potentially expand into other cancers and treatment monitoring globally.

In March 2024, Laboratory Corporation of America Holdings, a U.S.-based healthcare and diagnostics company, acquired BioReference Health from OPKO Health, Inc. for $237.5 million. This acquisition is intended to enhance Labcorp's capabilities and access in routine health screening. BioReference Health, a U.S.-based diagnostic laboratory company, offers testing services, including routine health screenings, oncology, urology, and reproductive and women’s health tests.

Major companies operating in the routine health screening market are Roche Holding AG, Thermo Fisher Scientific Inc., Siemens Healthineers, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Hologic Inc., Illumina Inc., SYNLAB International GmbH, Sysmex Corporation, QIAGEN N.V., Exact Sciences Corporation, RadNet Inc., Opko Health Inc., UNILABS, Amedes Holding GmbH, Natera Inc., Grail Inc., Trinity Biotech PLC, Cerba HealthCare S.A.S., Quidel Corporation, Innova Medical Group.

North America was the largest region in the routine health screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the routine health screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the routine health screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Routine health screening involves regular medical tests and check-ups designed to detect potential health issues before symptoms arise. These screenings are essential for monitoring overall health, identifying risk factors, and preventing serious conditions such as heart disease, diabetes, or cancer. Recommendations for screenings are typically based on factors such as age, gender, and health history, and they play a crucial role in maintaining long-term health and well-being.

The main types of routine health screenings include blood glucose tests, kidney function tests, bone profile tests, electrolyte tests, liver function tests, lipid profile tests, and others. A blood glucose test measures the level of glucose (sugar) in the blood to detect or manage diabetes. Samples for these tests can be obtained from blood, urine, serum, saliva, and other sources. Technologies used in these screenings include quantitative polymerase chain reaction (QPCR), quantitative fluorescence in situ hybridization (Q-FISH), immunoassays, medical imaging, single telomere length analysis (STELA), and others. Sample collection sites for these tests may include hospitals, homes, diagnostic laboratories, offices, and other locations.

The routine health screening market research report is one of a series of new reports that provides routine health screening market statistics, including routine health screening industry global market size, regional shares, competitors with a routine health screening market share, detailed routine health screening market segments, market trends and opportunities, and any further data you may need to thrive in the routine health screening industry. This routine health screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The routine health screening market consists of revenues earned by entities by providing services such as health assessments, screening procedures, consultations, telehealth screenings, and corporate wellness programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The routine health screening also includes sales of diagnostic test kits, medical devices, wearable health devices, and laboratory testing supplies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.